Blume-Jensen Peter
SEC CIK 1950499 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics, Inc. | Pres, CEO, Dir | 2.23M | $82.3K | $34.4K | 27 | 2022-11-14 | 2026-08-25 |
Most active insiders at ACRV, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Blume-Jensen Peter | Pres, CEO, Dir | $82.3K | $34.4K |
| 2 | Devroe Eric | COO | $17.2K | $1,214 |
| 3 | Levy Adam D. | CFO | $15.0K | $1,793 |
| 4 | Miller Mary | CLO | — | $1,380 |
| 5 | Gamelin Erick | Chief Development Off | — | $804.00 |
| 6 | Peterson Katharine | CAO | — | $203.01 |
| 7 | Levin Michaela | Chief Business Off | — | — |
| 8 | Palani Santhosh | Dir | — | — |
| 9 | Masson Kristina | EVP - Business Ops, Dir | — | — |
| 10 | DiRocco Derek | Dir | — | — |
Transactions 27
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-27 16:14 | 2026-08-25 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | S - Sale | $2.21 | -14.0K | 2.23M | -0.6% | -$31.0K | |
| 2026-08-20 16:07 | 2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | S - Sale | $2.01 | -1,229 | 2.24M | -0.1% | -$2,470 | |
| I | 2026-08-20 16:07 | 2026-08-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | S - Sale | $2.01 | -484 | 385.9K | -0.1% | -$972.84 |
| 2026-05-26 16:09 | 2026-05-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.79 | -13.7K | 2.25M | -0.6% | -$24.6K | |
| 2026-05-20 16:29 | 2026-05-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +180.1K | 2.26M | +9% | $0 | |
| I | 2026-05-20 16:29 | 2026-05-18 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +72.7K | 386.3K | +23% | $0 |
| 2026-05-18 16:10 | 2026-05-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.92 | -1,253 | 2.08M | -0.1% | -$2,406 | |
| I | 2026-05-18 16:10 | 2026-05-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.92 | -490 | 313.6K | -0.2% | -$940.80 |
| 2026-02-24 | 2026-02-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.53 | -14.3K | 2.08M | -0.7% | -$21.8K | |
| I | 2026-02-18 | 2026-02-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.63 | -579 | 314.1K | -0.2% | -$943.77 |
| 2026-02-18 | 2026-02-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.63 | -1,302 | 2.09M | -0.1% | -$2,122 | |
| 2026-01-16 | 2026-01-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | P - Purchase | $1.68 | +49.0K | 2.10M | +2% | +$82.3K | |
| 2025-05-23 | 2025-05-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.15 | -19.9K | 2.21M | -0.9% | -$22.9K | |
| I | 2025-05-16 | 2025-05-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.14 | -491 | 315.7K | -0.2% | -$559.74 |
| 2025-05-16 | 2025-05-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $1.14 | -59.8K | 2.23M | -3% | -$68.1K | |
| 2025-02-25 | 2025-02-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $5.54 | -19.9K | 2.29M | -0.9% | -$110.3K | |
| 2024-11-18 | 2024-11-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $7.92 | -59.8K | 2.36M | -2% | -$473.3K | |
| I | 2024-11-18 | 2024-11-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $7.92 | -490 | 316.8K | -0.2% | -$3,881 |
| 2024-08-23 | 2024-08-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $9.19 | -79.6K | 2.42M | -3% | -$731.7K | |
| 2024-08-16 | 2024-08-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $7.02 | -59.8K | 2.50M | -2% | -$419.6K | |
| 2024-05-16 | 2024-05-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $8.36 | -54.9K | 2.56M | -2% | -$459.1K | |
| 2024-02-16 | 2024-02-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $3.40 | -41.9K | 2.62M | -2% | -$142.3K | |
| 2023-11-16 | 2023-11-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | F - Tax | $5.08 | -239.0K | 2.66M | -8% | -$1.21M | |
| 2023-08-23 | 2023-08-21 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +494.0K | 2.90M | +21% | $0 | |
| D | 2023-06-01 | 2023-05-31 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | M - OptEx | $3.88 | +33.6K | 2.40M | +1% | +$130.4K |
| DM | 2022-11-16 | 2022-11-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +1.50M | 2.37M | +172% | $0 |
| DI | 2022-11-16 | 2022-11-14 | ACRV | Acrivon Therapeutics, Inc. | Blume-Jensen Peter | Pres, CEO, Dir | A - Grant | $0.00 | +26.7K | 320.7K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations